Research Article
Identification of Risk Factors Associated with Axillary Lymph Node Metastasis for Sentinel Lymph Node-Positive Breast Cancer Patients
Table 1
The relationship between clinicopathological characteristics and NSLN metastasis.
| | Clinicopathological characteristics | Total | NSLN status n (%) | Χ2 | | | (n = 566) | Negative | Positive | | (%) | n = 331 (58.5) | n = 235 (41.5) |
| | Age | | | | 3.673 | 0.055 | | <50 | 320 (56.5) | 176 (55.0) | 144 (45.0) | | | | ≥50 | 246 (43.5) | 155 (63.0) | 91 (37.0) | | |
| | Pathologic tumor size | | | | 0.931 | 0.335 | | T1 ≤2 cm | 293 (51.8) | 177 (60.4) | 116 (39.6) | | | | T2 ≤5 cm | 273 (48.2) | 154 (56.4) | 119 (43.6) | | |
| | Tumor type | | | | 0.865 | 0.649 | | Ductal | 530 (93.6) | 312 (58.9) | 218 (41.1) | | | | Lobular | 11 (1.9) | 5 (45.5) | 6 (54.5) | | | | Other | 25 (4.4) | 14 (56.0) | 11 (44.0) | | |
| | Nuclear grade | | | | 3.286 | 0.193 | | I | 24 (4.2) | 16 (66.7) | 8 (33.3) | | | | II | 256 (45.2) | 156 (60.9) | 100 (39.1) | | | | III | 250 (44.2) | 135 (54.0) | 115 (46.0) | | | | N/A | 36 (6.4) | 24 (66.7) | 12 (33.3) | | |
| | LVI | | | | 4.745 | 0.029 | | Present | 237 (41.9) | 126 (53.2) | 111 (46.8) | | | | Absent | 329 (58.1) | 205 (62.3) | 124 (37.7) | | |
| | Multifocality | | | | 0.029 | 0.865 | | Multifocal/yes | 78 (13.8) | 47 (60.3) | 31 (39.7) | | | | Unifocal/no | 471 (83.2) | 279 (59.2) | 192 (40.8) | | | | N/A | 17 (3.0) | 5 (29.4) | 12 (70.6) | | |
| | Surgery | | | | 0.004 | 0.953 | | Conservative | 293 (51.8) | 171 (58.4) | 122 (41.6) | | | | Mastectomy | 273 (48.2) | 160 (58.6) | 113 (41.4) | | |
| | ER receptor status | | | | 0.045 | 0.832 | | Positive | 507 (89.6) | 295 (58.2) | 212 (41.8) | | | | Negative | 57 (10.1) | 34 (59.6) | 23 (40.4) | | | | N/A | 2 (0.4) | 2 (100) | 0 (0) | | |
| | PR receptor status | | | | 0.119 | 0.730 | | Positive | 457 (80.7) | 265 (58.0) | 192 (42.0) | | | | Negative | 107 (18.9) | 64 (59.8) | 43 (40.2) | | | | N/A | 2 (0.4) | 2 (100) | 0 (0) | | |
| | HER2 expression | | | | 0.000 | 0.999 | | Positive | 117 (20.7) | 68 (58.1) | 49 (41.9) | | | | Negative | 406 (71.7) | 236 (58.1) | 170 (41.9) | | | | N/A | 43 (7.6) | 27 (62.8) | 16 (37.2) | | |
| | Ki-67 status | | | | 0.813 | 0.367 | | <14% | 82 (14.5) | 53 (64.6) | 29 (35.4) | | | | ≥14% | 450 (79.5) | 267 (59.3) | 183 (40.7) | | | | N/A | 34 (6.0) | 11 (32.4) | 23 (67.6) | | |
| | Number of positive SLNs | | | | 7.863 | 0.005 | | 1 | 420 (74.2) | 260 (61.9) | 160 (38.1) | | | | 2 | 146 (25.8) | 71 (48.6) | 75 (51.4) | | |
| | SLN metastasis ratio | | | | 19.902 | <0.001 | | <50% | 238 (42.0) | 165 (69.3) | 73 (30.7) | | | | ≥50% | 328 (58.0) | 166 (50.6) | 162 (49.4) | | |
| | Size of SLN metastasis | | | | 1.378 | 0.376 | | Micrometastasis | 12 (2.1) | 9 (75.0) | 3 (25.0) | | | | Macrometastasis | 554 (97.9) | 322 (58.1) | 232 (41.9) | | |
| | IHC-based subtype | | | | 2.517 | 0.642 | | Luminal A | 62 (11.0) | 42 (67.7) | 20 (32.3) | | | | Luminal/HER2– | 300 (53) | 173 (57.7) | 127 (42.3) | | | | Luminal/HER2+ | 91(16) | 53(58.2) | 38(41.8) | | | | HER2(+) | 22 (3.9) | 12 (54.5) | 10 (45.5) | | | | Triple-negative | 19 (3.4) | 12 (63.2) | 7 (36.8) | | | | N/A | 72 (12.7) | 39 (54.2) | 33 (45.8) | | |
|
|
NSLN, nonsentinel lymph node; SLN, sentinel lymph node; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
|
